Industry Outlook 1999/Fund Managers
Executive Summary
Are small-cap stocks stuck in a temporary down cycle? Or are they being hurt by structural changes in the investment community? True, investment funds have increased in size to such a degree that it has become financially impossible for most of them to invest in small cap companies. But small companies have things that large companies don't--innovative and differentiable products that are so crucial to the growth of large companies. {IN VIVO} talks with top-ranked health care analyst Dan LeMaitre of Cowen & Co. about the pressures on large and small device companies.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.